Past as Prologue-Use of Rubella Vaccination Program Lessons to Inform COVID-19 Vaccination.
COVID-19
Rubella vaccination
SARS-CoV-2
coronavirus disease
respiratory infections
severe acute respiratory syndrome coronavirus 2
vaccine-preventable diseases
viruses
zoonoses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
entrez:
11
12
2022
pubmed:
12
12
2022
medline:
15
12
2022
Statut:
ppublish
Résumé
The rapid rollout of vaccines against COVID-19 as a key mitigation strategy to end the global pandemic might be informed by lessons learned from rubella vaccine implementation in response to the global rubella epidemic of 1963-1965. That rubella epidemic led to the development of a rubella vaccine that has been introduced in all but 21 countries worldwide and has led to elimination of rubella in 93 countries. Although widespread introduction and use of rubella vaccines was slower than that for COVID-19 vaccines, the process can provide valuable insights for the continued battle against COVID-19. Experiences from the rubella disease control program highlight the critical and evolving elements of a vaccination program, including clearly delineated goals and strategies, regular data-driven revisions to the program based on disease and vaccine safety surveillance, and evaluations to identify the vaccine most capable of achieving disease control targets.
Identifiants
pubmed: 36502405
doi: 10.3201/eid2813.220604
pmc: PMC9745252
doi:
Substances chimiques
COVID-19 Vaccines
0
Rubella Vaccine
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
S225-S231Références
Vaccine. 2021 Feb 5;39(6):889-900
pubmed: 33454135
N Engl J Med. 2022 Mar 24;386(12):1176-1179
pubmed: 35196425
Lancet. 2022 Mar 5;399(10328):924-944
pubmed: 35202601
MMWR Morb Mortal Wkly Rep. 2005 Mar 25;54(11):279-82
pubmed: 15788995
MMWR Morb Mortal Wkly Rep. 2021 Nov 26;70(47):1640-1645
pubmed: 34818318
Epidemiol Rev. 2002;24(2):125-36
pubmed: 12762088
J Travel Med. 2022 May 31;29(3):
pubmed: 35262737
JAMA Pediatr. 2014 Feb;168(2):148-55
pubmed: 24311021
JAMA Pediatr. 2017 Aug 1;171(8):719-720
pubmed: 28654956
CDR (Lond Engl Rev). 1991 Mar 29;1(4):R33-7
pubmed: 1669769
MMWR Morb Mortal Wkly Rep. 2021 Oct 29;70(43):1520-1524
pubmed: 34710075
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1170-1176
pubmed: 34437525
MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):196-201
pubmed: 35143468
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145
pubmed: 35085224
J Infect Dis. 2011 Sep 1;204 Suppl 2:S713-7
pubmed: 21954271
Wkly Epidemiol Rec. 2011 Jul 15;86(29):301-16
pubmed: 21766537
Proc Natl Acad Sci U S A. 2021 Aug 24;118(34):
pubmed: 34376550
J Infect Public Health. 2021 Oct;14(10):1299-1312
pubmed: 34429257
Epidemiol Infect. 1991 Aug;107(1):17-30
pubmed: 1879482
Clin Infect Dis. 2006 Nov 1;43 Suppl 3:S123-5
pubmed: 16998770
BMJ. 1999 Mar 20;318(7186):769-70
pubmed: 10082699
J Travel Med. 2021 Oct 11;28(7):
pubmed: 34369565
Clin Infect Dis. 2006 Nov 1;43 Suppl 3:S164-8
pubmed: 16998777
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
JAMA. 1973 Aug 6;225(6):585-90
pubmed: 4740523